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1. Introduction
1.1. General concept
There is a convergence between ontogenesis and carcinogenesis. In theory all antigens
correspond to a specific stage of embryo/fetal development. These antigens – oncodevelop‐
mental proteins - are also present in homologous neoplatic tissues during cancer growth. The
first illustration of this theory is alpha-fetoprotein (AFP), a common tumor marker, which is
present during the normal development of central nervous system of the rat. Immunohisto‐
chemical analysis of the localization of AFP during normal development of the central nervous
system and in pathological homologous nervous tissues of teratocarcinoma, shows a remark‐
able parallelis [1]. A similar demonstration was demonstrated for serum albumin antigen and
blood group H antigen [2]. As AFP was a specific marker for neuronal cells, a search for a
specific marker of glial cells has constituted the next step in the nervous system research to
distinguish glial and neuronal cells, because the known markers were not totally specific. It
was demonstrated that the growth factor IGF-I (Insulin like Grow Factor I) [3-6] is present only
in glial cells, and absent in neuronal cells in normal and neoplastic developmen [7]. IGF-I is,
therefore, a specific marker of glioblastoma. The use of IGF-I for the study of malignant tumors,
including the gliomas, became the best choice as a marker [8-10].
1.2. Anti — Gene strategies
1.2.1. Antisense
For nearly twenty years various treatments of tumors, based on the injection of antibodies
directed against specific antigens and stem cells have been tested. The results were not
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successful because of non-selective affinity for the tumor. Moreover, direct injection of protein
coupled to an isotope such as iodine-125, has also posed the problem of the limited specificity
of the distribution of the protein [11]. After that, the researchers have approached the study in
a radically different way, trying to stop the production of IGF-I, acting directly on the mes‐
senger RNA [7,12].
Since 1978 it is known that antisense messengers are naturally produced and destroyed in the
process of DNA replicatio [13-17]. The authors successfully demonstrated that this phenom‐
enon is possible in twenty different species. Fortunately, the researchers could produce
artificial antisense messengers in a significant number [12,17-19]. Moreover, using antisense
oligonucleotides associated with the photoluminescent amino-terminated poly amido amine
dendrimer, they can be directly analyzed by fluorescence microscopy and flow cytometry [20].
The antisense sequences are capable of blocking the messenger RNA translation conducting
to block of specific protein synthesis.
1.2.2. Triple helix
Since the 90s, another approach in parallel with the strategy of antisense RNA has become
successful in gene therapy and clinical trials: the triple helix strategy [21-23]. The triple helix
technology (HT) is the newest approach, which belongs to the antisense approach and sensu
lato anti gene strategies. TH technology was discovered by PB Derwan and C. Helene [24,25]
and its action was defined as inhibition of gene expression at the level of transcription. In short,
specific oligonucleotide sequences (also called triple helix-forming oligonucleotides, TFOs) are
introduced into cells by transfection using chemical carriers, such as plasmid vectors which
can direct synthesis TFOs. The TFOs are linked to the genomic DNA forming the triple helix
structure with the target gene and inhibiting its transcription. The TFOs usually are directed
against sequences located in the promoter region of genes of interest [24]. Examples of the
inhibitory activity of TFOs on target genes involved in tumorigenesis are currently available.
This approach, based on the triple helix of DNA has been used for the inhibition of IGF-I, which
plays a major role in tumorigenesis [26]. Triplex strategy has also been applied to the inhibition
of Ras oncogenes which are the most frequently activated in human cancer. Transcription was
inhibited by human Hras TFOs targeting sequences recognized by the transcription factor Sp
I [27]. Moreover, synthesis of Human Tumor Necrosis Factor (TNF), which acts as an autocrine
growth factor in various tumor cell lines including neuroblastoma and glioblastoma has been
blocked by treatment with TFOs [28,29].
2. Experimental results
2.1. In vitro and in vivo experiments on glioma tumors
The vector of antisense type was transfected into established glioma C6 cell line. All transfected
cells have changed phenotype. Morphologically these cells had an elongated appearance.
Transfected glial cells have produced a large amount of antisense RNA [7,30].
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Regarding in vivo experiment, subcutaneous injection of C6 glioma cells into DBX rats have
produced a glioma tumor after ten days. When transfected glioma cells were injected (with
vector carrying the cDNA antisense against IGF-I) the tumors did not develop.
The experience was reproducible in 200 rats and the results were confirmatory. It was
demonstrated that if injected initially native C6 glioma cells were followed a week later by
injection into another point of subcutaneously transfected glial cells, the tumor developed, but
disappeared completely after 2 to 3 weeks [12].
The tumor examined histologically shortly before the death of animals, have shown an
important lymphocytes / plasmocytes infiltration. Histological analysis of the tumor during
its disappearance suggests that the essential mechanism is related to the presence of specifically
CD8 + cytotoxic T lymphocytes. Systematic analysis of all tissues showed that these lympho‐
cytes were of splenic origin, and were observed in very large quantities in the spleen of
experimental animals (10 to15%) [12,31,32].
2.2. Mechanism of glioma tumor destruction
The cytotoxic T CD8+ cell can exert its effect, if a bridge between CD8 and the antigen of class
I major histocompatibility complex (MHC) occurs [33-36]. Following transfection of glial cells
with the antisense cDNA of IGF-I, the expression of MHC-I in transfected glioma cells and in
vivo, is greatly enhanced (5 times). This mechanism may play a role in the cytotoxic response,
although not the only one involve [37]. The bearing tumor rats receiving injections of trans‐
fected cells, have revealed a very high rate of CD8 + cells. This anti-tumor immune response
has stopped the tumor development [12,31,38-40].
3. Application in clinical trial
3.1. Ethical committees
Approval for the clinical trial of gene therapy (based on the NIH clinical study No 1602,
Bethesda, Maryland, 24. 11. 1993) [41] was administered by the Commission of Bioethics at
the University of Medicine, Bromberg (No KB / 176/2001, 28. 06. 2002) and registered by
Wiley International Gene Therapy Clinical Trial database No. 635 and 636 (J  Gene Med,
updated 2002), and by NATO Science program 2003/2007 - USA, France, Poland, Germany
(LST 980 517).
3.2. Conditions
The NIH Committee raised a number of conditions. Initially, for all patients, tumor cells must
be isolated from biopsies and cells clones to be used should be only IGF-I and GFAP positive.
NIH also requires that all cells are irradiated with a dose of 5000 cGy before reinjection, to
avoid the possibility of subsequent cell divisions. After irradiation, the cells must be main‐
tained in cell culture for 24 hours.
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The elimination of the plasmid in the cells before injection is ensured by the possibility of a
deletion in vitro of the hygromicine for 2 to 3 weeks. (The safety of the method was guaranteed
by the use of an episomal vector without the risk of integration of the DNA vector).
Gene therapy will be preceded by a lymphocyte transformation test (TTL): in vitro, the
lymphocytes of patients with glioblastoma are brought into contact with their own tumor cells
transfected; the increase in tritiated thymidine incorporation will allow to demonstrate the
stimulation of immune cells.
The first stage is the biopsy, to harvest the cells for transfection in vitro. This step requires 4 to
6 weeks. Then, cells are frozen after verification that all cells are positive for IGF-I and GFA.
In case of cellular heterogeneity after cloning, only IGF-I positive population will be frozen
and preserved. The transfected cells should not produce IGF-I. The cells before injection should
be irradiated. The first authorization was granted in 1994 to 12 patients [30,41].
3.3. Methodology
Primary cultures of glioma cells were etablished from biopsies of human glioblastoma patients
[40]. The human glioma cell lines were transfected with plasmid vector of the "triple helix"
pMT-AG TH type [26]. Clones of transfected cells, no expressing IGF-I but expressing MHC-
I and B7 molecules, were selected one month after transfection. Prior to injection the transfected
cells were irradiated with cGy. The first injection was performed using only cell membranes
[42,43] derived from 100 000 cells, followed by two cell injection of 1 – 2 million cells, with
interval of one month each (subcutaneous injection in the left arm of patients). Blood was
collected before the first “membrane” vaccination, and then 3 weeks after the first and second
injection. The labeling of peripheral blood lymphocytes (PBL) was performed using mouse
monoclonal antibodies directed against cell surface antigens. The samples of monoclonal
antibodies were used for flow cytometric analysis as follows: FITC conjugated - (a) CD45, (b)
of CD4, (c) CD3, (d) CD25, (e) CD45RO, ( f) CD19 (g) CD8, (h) CD8CD11b +, (i) IgG1 control
antibody, and these conjugated with PE - (a) CD14, (b) CD8, (c) CD16 + CD6, (d) CD4 (CD8),
e) CD4 (CD8), (f) CD5, (g) CD8CD11b-, (h) CD8CD28, (i) IgG2 (18,27) [43].
4. Clinical results
The promising results were obtained in six patients at University Hospitals of Cleveland, in
two patients in Bangkok and in four patients at the University Hospital of Bromberg. Admit‐
ting that the group of glioblastoma patients treated with antisense/triple helix cell injection
has given the significant results, comparatively studied two cases of colon cancer and two cases
of prostate cancer patients were treated, after surgery and radiotherapy with this type of
“cellular therapy (Hospital of Bromberg).
Significant changes were observed mainly after the first cell vaccination. Phenotypic changes
in peripheral blood lymphocytes were as follows: an increase in the percentage of CD8 + T cells
accompanied in parallel by an increase of CD8 + CD11b- and CD8CD28 + molecules, after each
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Figure 1. Antisense anti – IGF-I therapy. After in vitro transfection of tumor cells with a vector containing IGF-I cDNA
in antisense orientation, the cells express IGF-I antisense RNA; the cells become negatively labeled with anti IGF-I anti‐
bodies, and positively with anti MHC-I and B7 antibodies. On the other hand, about half of these transfected cells be‐
come apoptotic. Both immune and apoptotic phenomena are related to signal transduction pathway. The injected
transfected cells including apoptotic cells, together with induced in vivo APC cells, activat T lymphocytes (CTLCD8 +
CD28 +). Activated CTL produce an antitumor immune response [40,44,47,61,79,80-83]. Abreviations: TAP 1,2 (trans‐
porter associated with antigen processing antigen); TK (tyrosine kinase); PI3K (phosphatidyinositol 3 kinase); PDK1
(phosphoinositide-dependent kinase 1); AKT (PKB, protein kinase B); Bcl 2 (key molecule of apoptose); GSK3 (glyco‐
gene synthetase kinase 3); GS (glycogene synthetase); MAPK (MAP kinase – mitogen activated protein kinase); PKC
(protein kinaseC C).
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of the three vaccinations. This alteration may reflect the increased activation of T cells cytotoxic
blood (Figure 1.). Additionally, it was observed an increased percentage of lymphocytes
positive for surface receptor of interleukin-2 (CD25). No changes were demonstrated in other
CD molecules [44]. In our ongoing work (new protocol), 4 and 5 injections of IGF-I TH cells
were introduced in patients with glioblastoma. After the fourth injection, the samples of the
blood obtained from treated patients have shown a progressive increase in CD8 and NK cells,
which highlights the effect of treatment on immune response. Also an increase of CD25
molecules was observed after the second and third injection. There was no difference before
or after vaccination in the levels of CD3, CD16 + CD56, CD19, CD5, CD45 and CD14. The only
side effect was a fever of 38°C noted after cell vaccinations. That probably corresponds to a
cellular immune response (T cell induction). These changes may reflect the increased activation
of cytotoxic T cells [36,45-47].
One glioblastoma patient who was treated at University Hospital of Cleveland, had lived 24
months from the time of diagnosis. Among other five glioblastoma patients treated in U.S.A.
(University Hospital of Cleveland), two of the patients have survived 19 months. The treatment
in U.S.A. has shown that the number of cell vaccines (between two and four) was not related
to median survival of the patients. Another group of three patients treated in the U.S.A. have
not responded so positively to therapy. These patients had an advanced disease with cerebral
edema before gene therapy and were also treated with high doses of decadron or related
steroids to reduce the effect of edema in CNS. Of course, this additional treatment has
produced a negative effect on immune response and survival of patients. In two of the four
patients with glioblastoma multiforme treated in Bromberg (NATO Science Program - USA /
France / Poland / Germany), the average survival has ranged from 19 to 24 months, whereas
the two patients in the control group survived 9.5 and 10 months respectively. Histopatho‐
logical examination of removed glioblastoma tumors has shown that subjects had developed
a necrosis around the tumor. Moreover the necrotic tissue surrounding the tumor has shown
an infiltration of CD4 + and CD8 + T lymphocytes [32]. As to colon and prostate cancer patients
the period of 19 months was also chosen as the end of clinical observations in all treated cancer
patients. At 19 months, all these cancer patients were alive and the treatments were well
tolerated. The PBL labelling results were similar to those obtained with glioblastoma patients
(Figure 2. A,B,C) [48].
5. Discussion
The significant clinical findings were published in 2006/2012; it was demonstrated that due to
the use of AS anti - IGF-I therapy following radiotherapy, the median survival of glioblastoma
patients has reached 21 months. In 2010 we have reported that this survival could be explained
by the immune anti-tumor response related to the increase of CD28 molecules in PBL cells
analyzed after every of two "vaccinations". Moreover, this phenomenon was also observed in
other tumors studied (four cases of liver cancer, colon, ovary, uterus and prostate). Phenotypic
changes in peripheral blood lymphocytes (PBL) were clearly observed in all types of cancer
treated with "cell therapy" - after every vaccination, an increase of CD8 + T lymphocytes,
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Figure 2. Flow cytometric “FACS” peripheral blood lymphocyte CD marker patterns following comparative therapies
in cancers of neuroectodermal origin - glioblastoma multiforme (A), entodermal origin – colon adenocarcinoma (B),
and mesodermal origin – prostate adenocaarcinoma (C). CD molecules were labelled in peripheral blood lymphocytes
(PBLs) obtained from prevaccinated and “vaccinated” patients. Each of the first column corresponds to data obtained
before vaccinations; each second and third column corresponds to data obtained after one and two successive cellular
vaccinations (IGF-I antisense/triple helix cells). Bar graphs represent the median value of the two cases. Data are ex‐
pressed as percent of positive cells when compared to the isotype control. Difference in percentage of CD8+ CD11b−
and CD8+ CD28+ subpopulations from the relevant patients before and after vaccination was strongly significant with
a range of P from 0.001 to 0.02 according to the Student’s t-test. The P value for CD8+, CD8+28+, and CD8+11b−
(below 0.01) is illustrated in the bar graph for statistical significance.
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particularly of CD8+11b-, accompanied by a characteristic shift of CD8+11b+ to CD8+11b-
(Figure 2.). This phenomenon was practically not significant in a group of patients treated only
with "membrane" injections (as applied to two patients with glioblastoma) [47,48].
Glioblastoma and other malignancies were recently successfully treated with antisense
therapy focused on TGF beta [49], using either antisense anti TGF beta expressing vector
[50,51] or direct use of antisense oligodeoxynucleotides [52,53]. The use of phosphorothioate
antisense oligonucleotides TGF beta2 (AP-12009, trabedersen) was initiated in patients with
tumors that showed overexpression of TGF beta, such as high-grade gliomas - anaplastic
astrocytoma (AA) or glioblastoma. Treatment was well tolerated. In 2007, the overall survival
time was about 24 months, and in the control group, survival was 20 months. Recently, in three
phase I/II studies and a randomized, active-controlled dose-finding phase IIb study, trabe‐
dersen treatment of high-grade glioma patients with recurrent or refractory tumor disease led
to long-lasting tumor responses and so far promising survival data [52,54,55]. The results of
clinical trials with other tumors that overexpress TGF beta have also been published recently
[52,56]. Recently, the antisense approach, using also antisense oligonucleotides, targeting
tumor neovascular trimer protein, laminin-411, was also proposed for clinical trial [57]. The
innovation concerns a polymeric nanobioconjugate drug based on biodegradable, nontoxic,
and nonimmunogenic polymalic acid as a universal delivery nanoplatform; this platform is
applied for synthesis of nanomedicine drug which passes through the blood brain tumor
barrier and tumor cell membrane. Other approach of antisense treatment, especially using
antisense IGF-I-receptor has been developed [58-60]. It seems that this therapy, could be more
efficient if the "cell vaccines" would be prepared after cell cloning for the expression of MHC-
I. The different examples of antisense strategy in experimental and clinical trials of gliomas
are showed in Table 1.
IGF-I Antisense vector
Clinical trial
Trojan et al. Biomed & Pharmacother 2010; 64(8):
TGF beta
& T cell therapy
Antisense
oligodeoxynucleotide
Clinical trial
Dietrich et al. Curr Opin Oncol 2010; 22(6):604
Laminin-411 Antisense
oligodeoxynucleotide
Clinical trial
Ding et al. Proc Natl Acad Sci USA 2010; 107(42):18143.
AKT2 Antisense oligonucleotide
Experimental therapy
Zhang et al. Oncol Rep 2010;24(1):65.
EGFR Antisense oligonucleotide
Experimental therapy
Li et al. Oncol Rep 2010; 23(6): 1585.
PED/PEA-15 (ERK1/2-
interacting protein)
Antisense oligonucleotide
Experimental therapy
Botta et al. Hum Gene Ther 2010; 21(9): 1067.
miR-21 & 5FU Antisense oligonucleotide
Experimental therapy
Ren et al. J Biomater Sci Polym Ed 2010; 21(3): 303.
miR-21 Antisense oligonucleotide Zhou et al. Lab Invest. 2010; 90(2): 144.
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IGF-I Antisense vector
Clinical trial
Trojan et al. Biomed & Pharmacother 2010; 64(8):
Experimental therapy
EGFR Antisense oligonucleotide
Experimental therapy
Kang et al. J Biomed Mater Res A 2010; 93(2): 585.
VEGF Antisense (vector)
Experimental therapy
Yang et al. J Neurooncol 2010; Aug 26 Epub
miR-21 Antisense oligonucleotide
Experimental therapy
Zhou et al. Oncol Rep 2010; 24(1): 195.
Telomerase and
tamoxifen
Antisense oligonucleotide
Experimental therapy
Wang et al., Mol Med Report. 2010; 3(6): 935.
c-Met Antisense oligonucleotide
Experimental therapy
Chu et al. Oncol Rep 2010; 24(1): 189.
IGF-I Antisense vector
Clinical trial
Trojan and Anthony, Curr Signal Transd Ther. 2011; 6(3): 411.
TGF beta Antisense
oligodeoxynucleotide
Clinical trial
Jashinsky et al., Curr Pharm Biotechnol. 2011; 12(12): 2203.
TGF beta Antisense
oligodeoxynucleotide
Clinical trial
Hau et al., Curr Pharm Biotechnol. 2011; 12(12): 2150.
miR-10b Antisense oligonucleotide
Experimental therapy
Sun et al., Brain Res. 2011;1389: 9
micro RNA-7 Antisense oligonucleotide
Experimental therapy
Lee et al., Radiother Oncol. 2011; 101(1):171.
uPAR Antisense vector
Experimental therapy
Raghu et al., Mol Cancer. 2011; 10: 130.
IGF-I Antisense vector
Clinical trial
Trojan et al., Chem Res Pract. 2012; doi:10.1155/2012/721873
miR-221/222 Antisense oligonucleotide
Experimental therapy
Hao et al., Oncol Rep. 2012; 27(5): 1504.
miR-143 and miR-145 Antisense oligonucleotide
Experimental therapy
Koo et al., BMC Cancer. 2012; 12: 143.
miR-1275 Antisense oligonucleotide
Experimental therapy
Katsushima et al., J Biol Chem. 2012 Jun 26. [Epub]
Table 1. Examples of experimental and clinical gene therapies of gliomas using antisense technology (selection of
articles of last two years).
In the strategies of anti TGF-beta and anti IGF-I and anti IGF-IR antisense techniques, the anti-
tumor immune response was designated as a primary mechanism involving growth factors
inhibited by antisense technology and its signaling pathway [37,51]. As PI3K/AKT/GWK3/GS
pathway is considered in antisense mechanism, it was recently demonstrated that also
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antisense anti-glycogen synthase (GS) cells express MHC-I molecules [44,61,62]. The IGF-I,
through its binding to IGF-IR, activates the PI3K/AKT transduction cascade related to the
pathway of apoptosis (IRS/PI3K/AKT/Bcl or AKT / Ca2 + or GSK3 or caspases). The end result
of IGF-I AS approach involves an inhibition of the pathway elements of TK/PI3K/AKT
inducing an in vivo immune response mediated by CD8 T cells and APC cells (Figure 1.) [44 ].
6. Conclusions
This review draws attention to the recent studies in cancer gene therapy, particularly of
glioblastoma treatment using anti - gene anti IGF-I approach. Although the number of clinical
trials of "antisense" type is much lower than those of pre-clinical experimental therapies, we
wish to emphasize that any experimental therapy is a potential clinical trial (Table 1.). The
current clinical strategies for the treatment of gliomas are usually a combination of chemo‐
therapy and use of different types of inhibitors (imatinib, gefitinib) including antibodies (i.e.
avastin), targeting growth factors and their receptors [63-66]. The new therapies are now
focusing on technology of inhibitors and antigene techniques (antisense or triple helix) used
alone or combined with drug treatment [67-71]. A pharmacological strategy - the use of
temozolomide introduced by R. Stupp, has offered a new hope for treatment of glioblastoma.
However, although median survival has reached almost two years, we are still far from victory
[72,73]. The new strategies proposing to target different growth factors, especially IGF-I, TGF-
beta or VEGF, their receptors and signaling pathway elements, seem to offer a promising
solution [54,73-76]. We would like to underline that the research on IGF-I which has resulted
in diagnostic application – the IGF-I being considered as one of the principal precancerous
markers [10,12], has conducted to experiments on suppression of IGF-I expression in tumors,
following directly by immuno-gene therapy of malignant tumors. Gene therapy, particularly
cellular imuno-gene therapy, and cellular immunotherapy are currently among the most
promising approaches for treatment of cancer diseases [66,68,77,78].
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